Using engineered nanoparticles to treat acute respiratory distress syndrome
Controlling complement to unleash nanomedicine for acute critical illnesses
This study is testing a new way to use tiny particles to deliver medicine right to the inflamed parts of the lungs in people with acute respiratory distress syndrome (ARDS), especially those dealing with COVID-19, to help reduce inflammation and improve breathing.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11014993 on NIH RePORTER |
What this research studies
This research focuses on developing specialized nanoparticles that can deliver drugs directly to the inflamed areas of the lungs in patients suffering from acute respiratory distress syndrome (ARDS). By targeting the microvasculature of affected organs, these nanoparticles aim to reduce inflammation and improve lung function. The study will also explore how to control the body's immune response to these nanoparticles to avoid adverse reactions while maximizing their therapeutic effects. Patients with ARDS, particularly those affected by COVID-19, may benefit from this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acute respiratory distress syndrome, especially those experiencing severe symptoms.
Not a fit: Patients with chronic respiratory conditions or those not experiencing acute respiratory distress may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for patients with acute respiratory distress syndrome.
How similar studies have performed: Previous research has shown promise in using targeted nanoparticles for drug delivery in similar conditions, indicating potential for success in this approach.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Brenner, Jacob — University of Pennsylvania
- Study coordinator: Brenner, Jacob
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.